Nucleotide sequence analysis of human T-cell leukemia virus type II. NLM AIDSLINE Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Nucleotide sequence analysis of human T-cell leukemia virus type II.

Princess Takamatsu Symp. 1984;15:165-75. Unique Identifier : AIDSLINE MED/86111558
Shimotohno K; Takahashi Y; Shimizu N; Takano M; Miwa M; Sugimura T

Abstract: The total nucleotide sequence of an infectious clone of human T-cell leukemia virus type II (HTLV-II) provirus was determined. The provirus has 8,952 nucleotides with a long terminal repeat (LTR) at each end. The LTR consists of 341 +/- 1 bases of U3, 248 +/- 1 bases of R, and 201 bases of U5 regions. There are gag, pol, and env coding frames in this order from the 5' end of the provirus as in other avian or mammalian retroviruses. A coding frame that can code 178 amino acid residues found between gag and pol is supposed to be for a protease that hydrolyses a gag precursor protein to matured gag proteins. The gag and protease genes and the pol and env genes, respectively, partly overlap. In the region termed X between env and 3' LTR, there are three major open reading frames. Oligopeptides deduced from the sequence of one of the open reading frame in HTLV-I were synthesized chemically, and antibodies against these peptides were raised in rabbits. With these antibodies, 41 kdalton and 38 kdalton proteins were detected in cells infected with HTLV-I and HTLV-II, respectively.
Keywords: Base Sequence *Genes, Viral HTLV-BLV Viruses/*GENETICS Repetitive Sequences, Nucleic Acid Retroviridae Proteins/GENETICS Support, Non-U.S. Gov't JOURNAL ARTICLE REVIEW

KWDbasesequenceKWDgenes,viralhtlv-blvviruses/KWDgeneticsrepetitivesequences,nucleicacidretroviridaeproteins/geneticssupport,non-uKWDsKWDgov'tjournalarticlereview
860530
M8650235

Copyright © 1986 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .